Indaptus Therapeutics (INDP) Cash from Operations (2020 - 2026)
Indaptus Therapeutics (INDP) posted quarterly Cash from Operations of 7009993.0 for Q1 2026, down 38.89% year-over-year from 11471248.68 in Q1 2025, and down 173.04% quarter-over-quarter from 2567427.0 in Q3 2025.
Indaptus Therapeutics (INDP) Cash from Operations (2020 - 2026) Analysis & Trends
Indaptus Therapeutics' Cash from Operations history runs 7 years deep, the most recent figure standing at 7009993.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 38.89% year-over-year to 7009993.0; the TTM figure through Mar 2026 stood at 18642736.0 (down 38.77% YoY), while the FY2024 annual figure was 12323188.0, up 8.07% from the prior year.
- Cash from Operations for Q1 2026 stood at 7009993.0, down from 2567427.0 in the prior quarter.
- The five-year high for Cash from Operations was 2106759.0 in Q2 2023, with the low at 7009993.0 in Q1 2026.
- The 5-year median for Cash from Operations is 3271954.5 (2022), against an average of 3590599.12.
- Peak annual rise in Cash from Operations reached 37.54% in 2022, while the deepest fall reached 277.64% in 2022.
- Indaptus Therapeutics' Cash from Operations stood at 2210913.0 in 2022, then decreased by 17.69% to 2601945.0 in 2023, then sank by 30.51% to 3395747.0 in 2024, then advanced by 24.39% to 2567427.0 in 2025, then slumped by 173.04% to 7009993.0 in 2026.
- Business Quant data shows INDP's Cash from Operations at 7009993.0 in Q1 2026, 2567427.0 in Q3 2025, and 4018189.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 728.46 Mn |
| 10 | Indaptus Therapeutics | 147.49 Mn | 135.93 Mn | - | -1.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.93 Mn |
| Jun 30, 2026 | -1.93 Mn |
| Mar 31, 2026 | -7.01 Mn |
| Mar 31, 2026 | -7.01 Mn |
| Sep 30, 2025 | -2.57 Mn |
| Sep 30, 2025 | -2.57 Mn |
| Jun 30, 2025 | -4.02 Mn |
| Jun 30, 2025 | -4.02 Mn |
| Mar 31, 2025 | -5.05 Mn |
| Mar 31, 2025 | -5.05 Mn |
| Dec 31, 2024 | -3.40 Mn |
| Dec 31, 2024 | -3.40 Mn |
| Sep 30, 2024 | -2.51 Mn |
| Sep 30, 2024 | -2.51 Mn |
| Jun 30, 2024 | -2.48 Mn |
| Jun 30, 2024 | -2.48 Mn |
| Mar 31, 2024 | -3.94 Mn |
| Mar 31, 2024 | -3.94 Mn |
| Dec 31, 2023 | -2.60 Mn |
| Dec 31, 2023 | -2.60 Mn |